News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma – Parker Institute for Cancer Immunotherapy
May 2, 2025, 18:25

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma – Parker Institute for Cancer Immunotherapy

Parker Institute for Cancer Immunotherapy shared a post on X:

“Few cancers rob young lives of time like Ewing sarcoma. New Scientific Reports research led by PICI Investigator Beatriz Carreno, PhD (Penn Medicine), with contributions from Gerald P. Linette, MD, PhD, and Carl June, MD, reveals LOXHD1 as a tumor-specific target for immunotherapy. Supported by Parker Institute for Cancer Immunotherapy.”

Title: LOXHD1 is an oncofusion-regulated antigen of Ewing sarcoma

Authors: Tatiana Blanchard, Pouya Faridi, Chong Xu, Adham S. Bear, Reyaz ur Rasool, Grace Huang, Terry C. C. Lim, Rochelle Ayala, Khatuna Gabunia, Mei Ji, Avery D. Posey Jr, John Scholler, Irfan A. Asangani, Anthony W. Purcell, Gerald P. Linette, Carl H. June and Beatriz M. Carreno.

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma - Parker Institute for Cancer Immunotherapy

You can read the Full Article on Scientific Reports.

Read about Ewing Sarcoma on OncoDaily.

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma - Parker Institute for Cancer Immunotherapy

More posts featuring Parker Institute for Cancer Immunotherapy.

Adham S. Bear Anthony W. Purcell Avery D. Posey Jr Beatriz M. Carreno cancer Carl H. June Carl June Chong Xu Ewing sarcoma Gerald P. Linette Grace Huang immunotherapy Irfan A. Asangani John Scholler Khatuna Gabunia LOXHD1 Mei Ji OncoDaily Oncology Parker Institute for Cancer Immunotherapy Pouya Faridi Reyaz ur Rasool Rochelle Ayala Scientific Reports Tatiana Blanchard Terry C. C. Lim
Special Coverage
Opinion
May 21, 2025, 09:58
Charles Jiang Shared Top Tips for First-Time Trainees at ASCO25
Blog
May 21, 2025, 09:36
Carmen Monge-Montero: Join Webinar on Migration, Displacement and Cancer Care Access in Europe
Blog
May 21, 2025, 09:04
Sebastian Szmit: Pleasure to Present My Expertise for the Cardio-Oncology Conference at Yale New Haven Hospital
Blog
May 21, 2025, 08:51
Margaret Fitch Will Be Keynote Speaker at ONS- Nigeria Upcoming Conference
Science
May 21, 2025, 08:27
Shankar Siva: PSMA PET Sensitivity Surpasses 90% in Prostate Cancer Meta-Analysis
Science
May 21, 2025, 08:22
Vivek Subbiah: Cancer Treatment Paradigms in The Precision Medicine Era
Blog
May 21, 2025, 08:19
GAMPER Webinar June 2025: Radiobiological Aspects of Radiotherapy and the Potential for Hypofractionation
Blog
May 21, 2025, 08:19
Cathy Eng: Two of my earlyonset Colorectal Cancer patients were honored at this annual run in Owensboro
Blog
May 21, 2025, 08:07
Amy Comander: Honored to Volunteer at Roxbury Community Health Fair
Blog
May 21, 2025, 08:02
Catherine Alix-Panabières: Honored to Highlight Our Research on Liquid Biopsy at the CHU de Montpellier
Blog
May 21, 2025, 07:53
Helena Linardou: Last Chance to Vote for the IASLC Board Election by May 22
Blog
May 21, 2025, 07:32
Ruben Mesa: Grateful to Take On a New Role as Clinical Leader for Advocate Health’s National Cancer Program